Imatinib-Sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis

Cell Host and Microbe

Volumn 10, Issue 5, 2011, Pages 475-485

  Napier, Ruth J ^a   Rafi, Wasiulla ^d   Cheruvu, Mani ^b   Powell, Kimberly R ^a   Zaunbrecher, M Analise ^a,b   Bornmann, William ^c   Salgame, Padmini ^d   Shinnick, Thomas M ^b   Kalman, Daniel ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; IMATINIB; PROTEIN TYROSINE KINASE; RIFABUTIN; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; CELL SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GRANULOMATOUS INFLAMMATION; HOST; HUMAN; HUMAN CELL; INFECTION PREVENTION; MACROPHAGE; MALE; MOUSE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CELL LINE; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TUBERCULOSIS; VIRULENCE;

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MUS; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 81755161197     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2011.09.010     Document Type: Article

References (41)

1. D. Bleed, C. Dye, and M.C. Raviglione Dynamics and control of the global tuberculosis epidemic Curr. Opin. Pulm. Med. 6 2000 174 179
2. A.E. Bolton, B. Peng, M. Hubert, A. Krebs-Brown, R. Capdeville, U. Keller, and M. Seiberling Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects Cancer Chemother. Pharmacol. 53 2004 102 106
3. E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B.J. Druker, and N.B. Lydon Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J. Pharmacol. Exp. Ther. 295 2000 139 145
4. E.A. Burton, R. Plattner, and A.M. Pendergast Abl tyrosine kinases are required for infection by Shigella flexneri EMBO J. 22 2003 5471 5479
5. E.A. Burton, T.N. Oliver, and A.M. Pendergast Abl kinases regulate actin comet tail elongation via an N-WASP-dependent pathway Mol. Cell. Biol. 25 2005 8834 8843
6. M.F. Cantwell, D.E. Snider Jr., G.M. Cauthen, and I.M. Onorato Epidemiology of tuberculosis in the United States, 1985 through 1992 JAMA 272 1994 535 539
7. M. Carroll, S. Ohno-Jones, S. Tamura, E. Buchdunger, J. Zimmermann, N.B. Lydon, D.G. Gilliland, and B.J. Druker CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 90 1997 4947 4952
8. H.F. Clark, and C.C. Shepard Effect of Environmental Temperatures on Infection with Mycobacterium Marinum (Balnei) of Mice and a Number of Poikilothermic Species J. Bacteriol. 86 1963 1057 1069
9. A.L. Dewar, A.C. Cambareri, A.C. Zannettino, B.L. Miller, K.V. Doherty, T.P. Hughes, and A.B. Lyons Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood 105 2005 3127 3132
10. B.J. Druker, C.L. Sawyers, R. Capdeville, J.M. Ford, M. Baccarani, and J.M. Goldman Chronic myelogenous leukemia Hematology Am Soc Hematol Educ Program. 2001 87 112
11. C. Dye, M.A. Espinal, C.J. Watt, C. Mbiaga, and B.G. Williams Worldwide incidence of multidrug-resistant tuberculosis J. Infect. Dis. 185 2002 1197 1202
12. C.A. Elwell, A. Ceesay, J.H. Kim, D. Kalman, and J.N. Engel RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry PLoS Pathog. 4 2008 e1000021
13. EMEA. (Sprycel, EMEA/H/C/709/II/08), (2008). Sprycel, INN-dasatinib. In European Public Assessment Report.(London: European Medicines Agency), pp. 1-46.
14. J.D. Ernst Macrophage receptors for Mycobacterium tuberculosis Infect. Immun. 66 1998 1277 1281
15. A. Ertmer, V. Huber, S. Gilch, T. Yoshimori, V. Erfle, J. Duyster, H.P. Elsässer, and H.M. Schätzl The anticancer drug imatinib induces cellular autophagy Leukemia 21 2007 936 942
16. P. Farmer, and J.Y. Kim Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus" BMJ 317 1998 671 674
17. J.M. Goldman, and B.J. Druker Chronic myeloid leukemia: current treatment options Blood 98 2001 2039 2042
18. M.G. Gutierrez, S.S. Master, S.B. Singh, G.A. Taylor, M.I. Colombo, and V. Deretic Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages Cell 119 2004 753 766
19. C. Hu, T. Mayadas-Norton, K. Tanaka, J. Chan, and P. Salgame Mycobacterium tuberculosis infection in complement receptor 3-deficient mice J. Immunol. 165 2000 2596 2602
20. S. Jayaswal, M.A. Kamal, R. Dua, S. Gupta, T. Majumdar, G. Das, D. Kumar, and K.V. Rao Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen PLoS Pathog. 6 2010 e1000839
21. R. Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, and F.J. Clubb Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat. Med. 12 2006 908 916
22. C. Kuijl, N.D. Savage, M. Marsman, A.W. Tuin, L. Janssen, D.A. Egan, M. Ketema, R. van den Nieuwendijk, S.J. van den Eeden, and A. Geluk Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 Nature 450 2007 725 730
23. S.L. Lebeis, and D. Kalman Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions Cell Host Microbe 5 2009 114 122
24. S. Mumprecht, M. Matter, V. Pavelic, and A.F. Ochsenbein Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections Blood 108 2006 3406 3413
25. J.F. Pielage, K.R. Powell, D. Kalman, and J.N. Engel RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization PLoS Pathog. 4 2008 e1000031
26. M.C. Raviglione, D.E. Snider Jr., and A. Kochi Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic JAMA 273 1995 220 226
27. P.M. Reeves, B. Bommarius, S. Lebeis, S. McNulty, J. Christensen, A. Swimm, A. Chahroudi, R. Chavan, M.B. Feinberg, and D. Veach Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases Nat. Med. 11 2005 731 739
28. P.M. Reeves, S.K. Smith, V.A. Olson, S.H. Thorne, W. Bornmann, I.K. Damon, and D. Kalman Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases J. Virol. 85 2011 21 31
29. B. Reinach, G. de Sousa, P. Dostert, R. Ings, J. Gugenheim, and R. Rahmani Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes Chem. Biol. Interact. 121 1999 37 48
30. N. Robinson, M. Wolke, K. Ernestus, and G. Plum A mycobacterial gene involved in synthesis of an outer cell envelope lipid is a key factor in prevention of phagosome maturation Infect. Immun. 75 2007 581 591
31. D.G. Russell, H.C. Mwandumba, and E.E. Rhoades Mycobacterium and the coat of many lipids J. Cell Biol. 158 2002 421 426
32. D.E. Snider Jr., and J.R. La Montagne The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis J. Infect. Dis. 169 1994 1189 1196
33. L.M. Stamm, J.H. Morisaki, L.Y. Gao, R.L. Jeng, K.L. McDonald, R. Roth, S. Takeshita, J. Heuser, M.D. Welch, and E.J. Brown Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motility J. Exp. Med. 198 2003 1361 1368
34. T.P. Stinear, T. Seemann, P.F. Harrison, G.A. Jenkin, J.K. Davies, P.D. Johnson, Z. Abdellah, C. Arrowsmith, T. Chillingworth, and C. Churcher Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis Genome Res. 18 2008 729 741
35. A. Swimm, B. Bommarius, Y. Li, D. Cheng, P. Reeves, M. Sherman, D. Veach, W. Bornmann, and D. Kalman Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals Mol. Biol. Cell 15 2004 3520 3529
36. T. Tønjum, D.B. Welty, E. Jantzen, and P.L. Small Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis J. Clin. Microbiol. 36 1998 918 925
37. N. van der Wel, D. Hava, D. Houben, D. Fluitsma, M. van Zon, J. Pierson, M. Brenner, and P.J. Peters M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells Cell 129 2007 1287 1298
38. N.C. Wolff, and R.L. Ilaria Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571 Blood 98 2001 2808 2816
39. WHO (World Health Organization) Tuberculosis Fact Sheet 2000 World Health Organization Geneva, Switzerland
40. G. Yogalingam, and A.M. Pendergast Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components J. Biol. Chem. 283 2008 35941 35953
41. Y.T.A. Zhang Molecular Genetics of Mycobacteria 2000 ASM Press Washington, DC